\BOOKMARK [0][-]{section*.2}{Sum\341rio}{}% 1
\BOOKMARK [0][-]{section*.3}{Lista de Figuras}{}% 2
\BOOKMARK [0][-]{section*.4}{Lista de Tabelas}{}% 3
\BOOKMARK [0][-]{chapter.1}{Introdu\347\343o}{}% 4
\BOOKMARK [1][-]{section.1.1}{Tumores cerebrais na inf\342ncia e adolesc\352ncia}{chapter.1}% 5
\BOOKMARK [1][-]{section.1.2}{Qual o objetivo desta obra}{chapter.1}% 6
\BOOKMARK [1][-]{section.1.3}{Como esta obra foi feita}{chapter.1}% 7
\BOOKMARK [2][-]{subsection.1.3.1}{Revis\343o da literatura}{section.1.3}% 8
\BOOKMARK [2][-]{subsection.1.3.2}{Protocolos de tratamento utilizados no HIAS}{section.1.3}% 9
\BOOKMARK [0][-]{chapter.2}{O tratamento de tumores cerebrais em crian\347as}{}% 10
\BOOKMARK [1][-]{section.2.1}{Tumores neuro-epiteliais de baixo grau}{chapter.2}% 11
\BOOKMARK [2][-]{subsection.2.1.1}{Avalia\347\343o cr\355tica de ensaios cl\355nicos}{section.2.1}% 12
\BOOKMARK [2][-]{subsection.2.1.2}{O panorama molecular dos gliomas de baixo grau}{section.2.1}% 13
\BOOKMARK [2][-]{subsection.2.1.3}{Quest\365es importantes ainda por responder}{section.2.1}% 14
\BOOKMARK [2][-]{subsection.2.1.4}{Conclus\365es}{section.2.1}% 15
\BOOKMARK [1][-]{section.2.2}{Tumores embrion\341rios e pineoblastoma}{chapter.2}% 16
\BOOKMARK [0][-]{chapter.3}{Esquemas de tratamento}{}% 17
\BOOKMARK [1][-]{section.3.1}{Introdu\347\343o}{chapter.3}% 18
\BOOKMARK [1][-]{section.3.2}{O que s\343o estes protocolos}{chapter.3}% 19
\BOOKMARK [1][-]{section.3.3}{Como utilizar estes protocolos}{chapter.3}% 20
\BOOKMARK [1][-]{section.3.4}{Declara\347\343o \351tica}{chapter.3}% 21
\BOOKMARK [1][-]{section.3.5}{Formato e contribui\347\365es}{chapter.3}% 22
\BOOKMARK [1][-]{section.3.6}{Uso n\343o padronizado \(off-label\) de medicamentos}{chapter.3}% 23
\BOOKMARK [0][-]{section*.10}{Refer\352ncias Bibliogr\341ficas}{}% 24
\BOOKMARK [0][-]{appendix.A}{Quimioterapia de primeira linha}{}% 25
\BOOKMARK [1][-]{section.A.1}{Glioma de baixo grau}{appendix.A}% 26
\BOOKMARK [2][-]{subsection.A.1.1}{Quimioterapia adjuvante: 52 semanas ou 1 ano}{section.A.1}% 27
\BOOKMARK [2][-]{subsection.A.1.2}{Modifica\347\365es de dose:}{section.A.1}% 28
\BOOKMARK [1][-]{section.A.2}{Meduloblastoma - Risco padr\343o \205 Adaptado dos ensaios CCG-9961 e ACNS0331}{appendix.A}% 29
\BOOKMARK [2][-]{subsection.A.2.1}{Radioquimioterapia: 7 semanas \(43 dias\)}{section.A.2}% 30
\BOOKMARK [2][-]{subsection.A.2.2}{Manuten\347\343o: 04 ciclos A e 04 ciclos B}{section.A.2}% 31
\BOOKMARK [2][-]{subsection.A.2.3}{Modifica\347\365es de dose:}{section.A.2}% 32
\BOOKMARK [1][-]{section.A.3}{Tumores malignos do SNc em menores de 3 anos \205 Adaptado do ensaio CCG 9921}{appendix.A}% 33
\BOOKMARK [2][-]{subsection.A.3.1}{Indu\347\343o: 5 ciclos \(VCEC\)}{section.A.3}% 34
\BOOKMARK [2][-]{subsection.A.3.2}{Manuten\347\343o: 08 ciclos}{section.A.3}% 35
\BOOKMARK [2][-]{subsection.A.3.3}{Modifica\347\365es de dose:}{section.A.3}% 36
\BOOKMARK [1][-]{section.A.4}{Ependimoma \205 Adaptado dos ensaios do COG e SIOP e de dados combinados da literatura}{appendix.A}% 37
\BOOKMARK [1][-]{section.A.5}{Tumores embrion\341rios \205 Adaptado dos ensaios COG-A99701 e ACNS0332}{appendix.A}% 38
\BOOKMARK [2][-]{subsection.A.5.1}{Radioquimioterapia: 7 semanas \(43 dias\)}{section.A.5}% 39
\BOOKMARK [2][-]{subsection.A.5.2}{Manuten\347\343o: 06 ciclos}{section.A.5}% 40
\BOOKMARK [2][-]{subsection.A.5.3}{Modifica\347\365es de dose:}{section.A.5}% 41
\BOOKMARK [1][-]{section.A.6}{Glioma de alto grau \205 Adaptado do ensaio ACNS0423}{appendix.A}% 42
\BOOKMARK [2][-]{subsection.A.6.1}{Indu\347\343o: 6 semanas \(radioquimioterapia\)}{section.A.6}% 43
\BOOKMARK [2][-]{subsection.A.6.2}{Manuten\347\343o: 06 ciclos}{section.A.6}% 44
\BOOKMARK [2][-]{subsection.A.6.3}{Modifica\347\365es de dose:}{section.A.6}% 45
\BOOKMARK [0][-]{appendix.B}{Quimioterapia de resgate \(doen\347a recorrente/progressiva\)}{}% 46
\BOOKMARK [1][-]{section.B.1}{Tumores do SNC recorrentes}{appendix.B}% 47
\BOOKMARK [2][-]{subsection.B.1.1}{Quimioterapia: 10 ciclos}{section.B.1}% 48
\BOOKMARK [2][-]{subsection.B.1.2}{Modifica\347\365es de dose:}{section.B.1}% 49
\BOOKMARK [1][-]{section.B.2}{Ifosfamida/Etoposido}{appendix.B}% 50
\BOOKMARK [2][-]{subsection.B.2.1}{Resgate: 03 ciclos - repetir enquanto n\343o houver progress\343o}{section.B.2}% 51
\BOOKMARK [2][-]{subsection.B.2.2}{Modifica\347\365es de dose:}{section.B.2}% 52
\BOOKMARK [1][-]{section.B.3}{Ifosfamida, carboplatina e etoposido \(ICE\)}{appendix.B}% 53
\BOOKMARK [2][-]{subsection.B.3.1}{Resgate: 02 ciclos - repetir enquanto n\343o houver progress\343o}{section.B.3}% 54
\BOOKMARK [2][-]{subsection.B.3.2}{Modifica\347\365es de dose:}{section.B.3}% 55
\BOOKMARK [0][-]{appendix.C}{Quimioterapia neoadjuvante}{}% 56
\BOOKMARK [1][-]{section.C.1}{Vimblastina neoadjuvante}{appendix.C}% 57
\BOOKMARK [2][-]{subsection.C.1.1}{Esquema: 6 semanas}{section.C.1}% 58
\BOOKMARK [2][-]{subsection.C.1.2}{Modifica\347\365es de dose:}{section.C.1}% 59
\BOOKMARK [1][-]{section.C.2}{Ifosfamida, carboplatina e etoposido neoadjuvante}{appendix.C}% 60
\BOOKMARK [2][-]{subsection.C.2.1}{Dois ciclos - repetir uma vez se necess\341rio e n\343o houver progress\343o}{section.C.2}% 61
\BOOKMARK [2][-]{subsection.C.2.2}{Modifica\347\365es de dose:}{section.C.2}% 62
\BOOKMARK [0][-]{appendix.D}{Quimioterapia metron\364mica}{}% 63
\BOOKMARK [1][-]{section.D.1}{Vimblastina metron\364mica}{appendix.D}% 64
\BOOKMARK [2][-]{subsection.D.1.1}{Esquema 1: 6 semanas - usar esquema 1 ou 2, n\343o ambos}{section.D.1}% 65
\BOOKMARK [2][-]{subsection.D.1.2}{Esquema 2: 6 semanas - usar esquema 1 ou 2, n\343o ambos}{section.D.1}% 66
\BOOKMARK [2][-]{subsection.D.1.3}{Modifica\347\365es de dose:}{section.D.1}% 67
\BOOKMARK [0][-]{appendix.E}{Qumioterapia alternativa \(substitu\355dos por atualiza\347\365es\)}{}% 68
\BOOKMARK [1][-]{section.E.1}{Glioma de baixo grau \205 Adaptado do ensaio COG-A9952}{appendix.E}% 69
\BOOKMARK [2][-]{subsection.E.1.1}{Indu\347\343o: 10 semanas}{section.E.1}% 70
\BOOKMARK [2][-]{subsection.E.1.2}{Manuten\347\343o: 48 semanas \(08 blocos de 6 semanas\)}{section.E.1}% 71
\BOOKMARK [2][-]{subsection.E.1.3}{Modifica\347\365es de dose:}{section.E.1}% 72
\BOOKMARK [1][-]{section.E.2}{Glioma de alto grau \205 Adaptado do ensaio ACNS0126}{appendix.E}% 73
\BOOKMARK [2][-]{subsection.E.2.1}{Indu\347\343o: 6 semanas \(radioquimioterapia\)}{section.E.2}% 74
\BOOKMARK [2][-]{subsection.E.2.2}{Manuten\347\343o: 10 ciclos}{section.E.2}% 75
\BOOKMARK [2][-]{subsection.E.2.3}{Modifica\347\365es de dose:}{section.E.2}% 76
\BOOKMARK [1][-]{section.E.3}{Glioma de alto grau \205 Adaptado do ensaio HIT-GBM-D}{appendix.E}% 77
\BOOKMARK [2][-]{subsection.E.3.1}{Indu\347\343o: 6 semanas \(radioquimioterapia\)}{section.E.3}% 78
\BOOKMARK [2][-]{subsection.E.3.2}{Manuten\347\343o: 08 ciclos}{section.E.3}% 79
\BOOKMARK [2][-]{subsection.E.3.3}{Modifica\347\365es de dose:}{section.E.3}% 80
\BOOKMARK [1][-]{section.E.4}{Ependimoma n\343o metast\341tico \205 Adaptado dos ensaios ACNS0121 e ACNS0831}{appendix.E}% 81
\BOOKMARK [2][-]{subsection.E.4.1}{Indu\347\343o: 2 ciclos \(pr\351-radioterapia\)}{section.E.4}% 82
\BOOKMARK [2][-]{subsection.E.4.2}{Manuten\347\343o: 04 ciclos \(VCEC\)}{section.E.4}% 83
\BOOKMARK [2][-]{subsection.E.4.3}{Modifica\347\365es de dose:}{section.E.4}% 84
\BOOKMARK [0][-]{appendix.F}{Terapia alvo, imunoterapia, terapia biol\363gica}{}% 85
\BOOKMARK [1][-]{section.F.1}{Interferon para craniofaringiomas}{appendix.F}% 86
\BOOKMARK [2][-]{subsection.F.1.1}{Esquema: 4 semanas - repetir 2 a 6 vezes}{section.F.1}% 87
\BOOKMARK [1][-]{section.F.2}{Interferon para histiocitose n\343o Langerhans}{appendix.F}% 88
\BOOKMARK [2][-]{subsection.F.2.1}{Esquema: 4 semanas - continuar at\351 progress\343o}{section.F.2}% 89
\BOOKMARK [1][-]{section.F.3}{Everolimo para astrocitoma subependim\341rio de c\351lulas gigantes}{appendix.F}% 90
\BOOKMARK [2][-]{subsection.F.3.1}{Esquema: cont\355nuo at\351 progress\343o}{section.F.3}% 91
\BOOKMARK [0][-]{appendix.G}{Protocolos experimentais \(estudos cl\355nicos\)}{}% 92
\BOOKMARK [1][-]{section.G.1}{VALQUIRIA \(VALPROATO, QUIMIOTERAPIA E RADIOTERAPIA - protocolo experimental cancelado}{appendix.G}% 93
\BOOKMARK [2][-]{subsection.G.1.1}{Resumo do tratamento:}{section.G.1}% 94
\BOOKMARK [2][-]{subsection.G.1.2}{Indu\347\343o: 6 semanas \(radioquimioterapia\)}{section.G.1}% 95
\BOOKMARK [2][-]{subsection.G.1.3}{Manuten\347\343o: 08 ciclos}{section.G.1}% 96
\BOOKMARK [2][-]{subsection.G.1.4}{Modifica\347\365es de dose:}{section.G.1}% 97
